MangoRx Acquires Patent Portfolio For Total Of $20M Through Issuance Of 980K Of 6% Series C Convertible Preferred Shares
Author: Benzinga Newsdesk | April 25, 2024 08:34am
Mangoceuticals, Inc. (NASDAQ:
MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair
Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce that it has acquired a global patent portfolio for a pioneering oral solution and application aimed to combat and prevent a spectrum of infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV) (the "Patent Portfolio") from Intramont Technologies, Inc. ("Intramont"), pursuant to a Patent Purchase Agreement ("PPA").
Posted In: MGRX